Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSC | P53634 | 2/20 | 0.46 |
| ▸ | CTSH | P09668 | 1/20 | 0.46 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.39 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19023044 | 0.83 | MGLL (0.50) | EPHX2 | |
| SCHEMBL408174 | 0.83 | USP30 (0.58) | KDM4EALDH1A1USP30 | |
| SCHEMBL19041868 | 0.83 | USP30 (0.58) | KDM4EALDH1A1USP30 | |
| SCHEMBL19037361 | 0.83 | USP30 (0.58) | KDM4EALDH1A1USP30 | |
| SCHEMBL11238378 | 0.82 | SMN1; SMN2 (0.57) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6954138 | 0.82 | SMN1; SMN2 (0.57) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11238381 | 0.82 | SMN1; SMN2 (0.57) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2532124 | 0.80 | EPHX2 (0.53) | GAAEPHX2SCD5SRD5A1USP30 | |
| SCHEMBL796858 | 0.80 | EPHX2 (0.53) | GAAEPHX2SCD5SRD5A1USP30 | |
| SCHEMBL796833 | 0.80 | EPHX2 (0.53) | GAAEPHX2SCD5SRD5A1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | CTSV 168/4885CTSL 180/4885CTSB 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.